翰宇药业：与三生蔓迪签署系列商业化协议，减重药物预计年销售峰值3000万支

Group 1 - The core agreement between Hanyu Pharmaceutical and Zhejiang Sanofi Mandi Pharmaceutical includes the signing of a series of commercialization documents for the production and supply of Semaglutide injection for weight loss [1] - The supply price will be based on non-binding sales forecasts, with tiered pricing based on annual purchase volumes of ≤5 million, 5-10 million, and >10 million units [1] - The expected peak annual sales volume is projected to reach 30 million units, subject to actual commercial batch orders [1] Group 2 - The Semaglutide injection is being submitted as a Class 2 modified new drug and will be produced concurrently in both China and the United States [1]